Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000692891 | SCV000820739 | uncertain significance | Immunodeficiency, common variable, 7 | 2022-08-23 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid, which is acidic and polar, with valine, which is neutral and non-polar, at codon 243 of the CR2 protein (p.Asp243Val). This variant is present in population databases (rs368883636, gnomAD 0.09%). This variant has not been reported in the literature in individuals affected with CR2-related conditions. ClinVar contains an entry for this variant (Variation ID: 571680). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002532227 | SCV003537631 | uncertain significance | Inborn genetic diseases | 2022-09-22 | criteria provided, single submitter | clinical testing | The c.728A>T (p.D243V) alteration is located in exon 4 (coding exon 4) of the CR2 gene. This alteration results from a A to T substitution at nucleotide position 728, causing the aspartic acid (D) at amino acid position 243 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Genome- |
RCV000692891 | SCV004180410 | uncertain significance | Immunodeficiency, common variable, 7 | 2023-04-11 | criteria provided, single submitter | clinical testing |